present
specif
treatment
coronaviru
infect
howev
prior
outbreak
help
deciph
main
pharmacolog
target
virus
therapi
focus
target
proteas
helicas
polymeras
use
immunomodul
interferon
corticosteroid
zumla
et
al
ribavirin
alon
combin
ifn
common
therapeut
intervent
patient
sar
mer
khalid
et
al
also
proteas
inhibitor
use
vitro
vivo
block
coronaviru
replic
lopinavir
lpv
ritonavir
rtv
proteas
inhibitor
current
use
hiv
therapi
could
block
sarscov
merscov
main
proteas
savarino
combin
lopinavir
ritonavir
ribavirin
associ
improv
clinic
outcom
compar
ribavirin
alon
sarscovinfect
patient
lai
merscov
outbreak
food
drug
administr
approv
use
ritonavirlopinavir
base
mainli
data
obtain
vitro
studi
sheahan
et
al
altogeth
data
support
assumpt
proteas
inhibitor
may
antivir
effect
block
coronaviru
main
proteas
howev
like
rna
virus
main
challeng
associ
antivir
therapi
select
resist
variant
mechan
gener
divers
coronaviru
relat
moder
error
rate
polymeras
proofread
capac
homolog
heterolog
recombin
factor
lead
antigen
drift
shift
similar
describ
influenza
virus
menacheri
et
al
thu
viral
replic
produc
divers
popul
genom
variant
differ
fit
profil
variant
could
associ
develop
drug
resist
yin
wunderink
pruijsser
denison
ongo
effort
toward
discov
effici
drug
prevent
treat
infect
includ
prior
structur
pharmacolog
knowledg
gain
coronaviru
outbreak
base
work
establish
compar
theoret
studi
ration
potenti
use
proteas
inhibitor
treatment
infect
protein
sequenc
main
proteas
individu
retriev
genbank
access
number
shown
phylogenet
tree
figur
fig
sarscov
sever
batcov
genu
betacoronaviru
coordin
sarscov
main
proteas
obtain
protein
data
bank
pdb
code
respect
also
proteas
bound
lopinavir
pdb
code
bat
coronaviru
pdb
code
evalu
pdb
file
use
comput
analysi
optim
remov
cocrystal
molecul
crystallograph
water
molecul
hydrogen
ad
partial
charg
assign
atom
obtain
pdb
file
protein
submit
restrain
molecular
mechan
refin
molecular
dynam
simul
describ
studi
perform
namd
phillip
et
al
vega
zz
pedretti
et
al
vanommeslaegh
et
al
describ
ortega
et
al
follow
structur
analysi
bind
pocket
develop
use
castp
softwar
use
http
stsbioeuiceducastp
server
ligandbind
pocket
locat
catalyt
site
obtain
manual
verifi
priori
dock
approach
lopinavir
use
achil
blind
dock
server
et
al
structur
inhibitor
obtain
pubchem
also
public
librari
proteas
inhibitor
obtain
pubchem
zinc
databas
molecular
dock
perform
vinavegazz
run
conduct
compound
result
priorit
accord
predict
bind
energi
kcalmol
result
obtain
dock
simul
visual
biovia
discoveri
studio
visual
softwar
comprehens
analysi
physicochem
descriptor
well
adm
paramet
pharmacokinet
properti
druglik
natur
medicin
chemistri
top
compound
obtain
librari
virtual
screen
carri
use
swissadm
tool
tool
asset
websit
http
wwwswissadmech
phylogenet
analysi
main
proteas
protein
sequenc
sarscov
batcov
shown
figur
fig
result
agreement
recent
report
independ
introduct
batcov
differ
spillov
led
introduct
sarscov
batcov
rhinolophu
affini
probabl
ancestor
new
viru
wong
et
al
sequenc
whole
main
proteas
batcov
share
ident
merscov
proteas
ident
figur
fig
main
proteas
sequenc
highli
conserv
among
sarslik
coronavirus
human
relat
cov
anim
figur
fig
sarscov
protein
exhibit
sequenc
ident
figur
fig
figur
fig
show
represent
batcov
sarscov
main
proteas
inde
similar
structur
observ
particularli
compar
sarscov
proteas
although
differ
one
interestingli
proteas
share
amino
acid
involv
drug
interact
sarscov
proteas
later
exhibit
amino
acid
involv
interact
figur
fig
proteas
activ
site
surfac
access
solvent
sarscov
figur
fig
silico
data
demonstr
differ
proteas
inhibitor
use
could
interact
activ
site
proteas
produc
interact
bind
energi
lower
kcalmol
howev
compound
produc
strongest
interact
activ
site
saquinavir
bind
energi
kcalmol
tabl
tab
bind
energi
main
proteas
saquinavir
sqv
lpv
slightli
higher
similar
one
proteas
tabl
tab
interact
lpv
sqv
rtv
main
proteas
shown
figur
fig
differ
aminoacid
involv
interact
drug
also
shown
order
contribut
studi
relat
develop
effect
drug
work
evalu
broad
librari
proteas
inhibitor
avail
zinc
databas
compound
pubchem
compound
molecular
dock
compound
priorit
base
bind
energi
top
compound
cluster
use
hierarch
matrix
repres
heat
map
figur
fig
compound
could
cluster
three
big
group
base
chemic
structur
also
bind
energi
chemic
motiv
compound
shown
tabl
tab
interestingli
output
virtual
screen
least
compound
repres
chemic
cluster
bind
energi
around
kcalmol
obtain
scaffold
could
use
lead
compound
chemic
optim
develop
potent
inhibitor
structur
main
adm
paramet
inhibitor
shown
figur
fig
gener
compound
shown
physicochem
paramet
expect
valu
good
drug
due
rapid
spread
affect
countri
therapeut
altern
urgent
requir
viral
main
proteas
play
pivot
role
coronaviru
replic
enzym
respons
cleavag
polyprotein
produc
function
protein
pack
virion
molecular
studi
proteas
show
viru
high
homolog
sarscov
proteas
previou
data
suggest
use
proteas
inhibitor
potenti
inhibitor
sarscov
proteas
special
use
therapi
proteas
aspartyl
proteas
coronaviru
cystein
proteas
howev
inhibit
proteas
inhibitor
could
driven
similar
mechan
one
beststudi
model
antivir
research
target
well
character
inhibit
drug
broadli
studi
proteas
inhibitor
play
main
role
therapi
furthermor
compound
shown
inhibitori
effect
proteas
pathogen
leishmania
malaria
valdivieso
et
al
sonoiki
et
al
de
wild
et
al
thu
use
proteas
inhibitor
viral
speci
could
support
nonspecif
proteas
inhibit
previou
report
show
inhibit
sarscov
proteas
proteas
inhibitor
use
therapi
interest
pharmacolog
target
treat
previous
scientif
report
show
proteas
inhibitor
could
decreas
sarscov
replic
savarino
nevertheless
proteas
inhibitor
show
efficaci
viru
jenwitheesuk
samudrala
base
work
establish
silico
approach
valid
inhibit
proteas
proteas
inhibitor
result
show
main
proteas
inhibitor
use
therapi
could
produc
decreas
proteas
activ
coronaviru
enzym
compound
highest
bind
affin
saquinavir
preliminari
report
show
patient
infect
treat
lopinavir
could
achiev
viral
clearanc
lim
et
al
studi
suggest
drug
sqv
lpv
shown
slightli
higher
compar
bind
energi
proteas
thu
base
safeti
profil
sqv
lpv
could
use
therapi
andor
preexposur
prophylaxi
reduc
new
infect
addit
data
obtain
prior
outbreak
clinic
result
obtain
use
proteas
inhibitor
patient
infect
result
shown
support
use
proteas
inhibitor
treat
addit
contribut
develop
antivir
drug
work
experiment
compound
proteas
evalu
virtual
screen
compound
show
compar
bind
energi
valu
proteas
observ
sqv
lpv
rtv
adm
absorpt
distribut
metabol
excret
paramet
estim
new
drug
significantli
help
reduc
pharmacokineticsrel
failur
clinic
phase
result
evid
compound
could
suitabl
medicin
chemistri
optim
produc
second
gener
inhibitor
specif
potent
antivir
evalu
polymeras
inhibitor
remdesivir
nucleotid
analog
current
clinic
trial
ebola
viru
alon
combin
chloroquin
inhibitor
lysosom
acidif
interest
result
wang
et
al
de
wit
et
al
therefor
propos
combinatori
therapi
could
feasibl
approach
start
therapeut
scheme
could
includ
remdesivir
disadvantag
intraven
administr
proteas
inhibitor
lopinavir
saquinavir
nevertheless
preclin
clinic
data
requir
support
develop
new
therapi
